We found 23 comfortable shoes you’ll want this year. Shop sales on Crocs, Hoka, Asics, Birkenstock and more from DSW, Amazon, ...

The holidays may be over, but that doesn’t mean the sales have ended. For anyone with items left on their Christmas list, ...

From the outset of the Second World War, Australian women were aware of the changing role of British women in supporting Britain’s war effort. To help “do their bit” for Australia’s war effort, women ...

Suleiman Sandal, a prominent figure within the Sudanese Revolutionary Front (SRF), announced the proposal on Wednesday following a contentious debate within the Tagadum coalition, a broad alliance ...

Teva and Sanofi’s duvakitug achieved remission rates up to 47.8% in trials. The drug’s efficacy surpasses that of rivals like Merck and Roche in placebo-adjusted responses. The TL1A class ...

A significant proportion of subjects with UC who were treated with the therapy achieved clinical remission in the study. Credit: Wasan Tita/Shutterstock. Sanofi and Teva Pharmaceuticals have reported ...

Chesnot / Getty Images Teva Pharmaceuticals and Sanofi on Tuesday reported positive results in a Phase 2b trial of their drug for ulcerative colitis and Crohn's disease. The companies plan to ...

Teva Pharmaceuticals’TEVA0.63%increase; green up pointing triangle shares soared and Sanofi’sSAN-0.33%decrease; red down pointing triangle stock moved higher following positive results from ...

The anti-TL1A antibody allowed significantly more inflammatory bowel disease (IBD) patients to go into remission than those taking placebo treatment. Teva announced it was partnering with Sanofi to ...

On Tuesday, Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) and Sanofi SA’s (NASDAQ:SNY) Phase 2b RELIEVE UCCD study met its primary endpoints in patients with ulcerative colitis (UC ...

ADRs of Teva Pharmaceutical (NYSE:TEVA) and Sanofi (NASDAQ:SNY) traded higher in the premarket on Tuesday after the companies said that their experimental antibody therapy, duvakitug, reached the ...

Merck is working on the monoclonal antibody MK-7240—formerly known as PRA023—which it acquired in its $10.8 billion buyout of Prometheus Biosciences last year. In phase 2 results disclosed in ...